Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging peptide therapeutics for the treatment of ovarian cancer.
Veneziani AC, Gonzalez-Ochoa E, Oza AM. Veneziani AC, et al. Among authors: gonzalez ochoa e. Expert Opin Emerg Drugs. 2023 Dec;28(2):129-144. doi: 10.1080/14728214.2023.2218643. Epub 2023 Jun 7. Expert Opin Emerg Drugs. 2023. PMID: 37282529 Review.
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D, Danesh A, Torti D, Torchia J, Fortuna A, Singh S, Irving M, Marsh K, Lam B, Speers V, Yosifova A, Oaknin A, Madariaga A, Dhani NC, Bowering V, Oza AM, Pugh TJ. Lheureux S, et al. Among authors: gonzalez ochoa e. Clin Cancer Res. 2023 Sep 15;29(18):3706-3716. doi: 10.1158/1078-0432.CCR-23-0797. Clin Cancer Res. 2023. PMID: 37327320 Free PMC article. Clinical Trial.
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S. Gonzalez-Ochoa E, et al. Int J Gynecol Cancer. 2023 Aug 7;33(8):1208-1214. doi: 10.1136/ijgc-2023-004491. Int J Gynecol Cancer. 2023. PMID: 37380217 Free PMC article. Clinical Trial.
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
Gonzalez-Ochoa E, Veneziani AC, Oza AM. Gonzalez-Ochoa E, et al. Clin Med Insights Oncol. 2023 Jul 25;17:11795549231187264. doi: 10.1177/11795549231187264. eCollection 2023. Clin Med Insights Oncol. 2023. PMID: 37528890 Free PMC article. Review.
Heterogeneity and treatment landscape of ovarian carcinoma.
Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Veneziani AC, et al. Among authors: gonzalez ochoa e. Nat Rev Clin Oncol. 2023 Dec;20(12):820-842. doi: 10.1038/s41571-023-00819-1. Epub 2023 Oct 2. Nat Rev Clin Oncol. 2023. PMID: 37783747 Review.
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers.
Madariaga A, Jivraj N, Soberanis Pina P, Somji F, Truong T, Melwani S, Lovas M, Gogos TA, Sajewycz K, Bhat G, Alqaisi H, Gonzalez-Ochoa E, Veneziani A, Garg V, Dhani NC, Grant R, Bowering V, Oza AM, Wang L, Berlin A, Lheureux S. Madariaga A, et al. Among authors: gonzalez ochoa e. Int J Gynecol Cancer. 2024 Oct 7;34(10):1612-1618. doi: 10.1136/ijgc-2024-005490. Int J Gynecol Cancer. 2024. PMID: 38821545
A prevalence study in Guadalajara, Mexico, comparing tuberculin skin test and QuantiFERON-TB Gold In-Tube.
Plascencia Hernández A, González Sánchez RM, Hernández Cañaveral II, Luévanos Velázquez A, Martínez Arce PA, González Díaz A, Sandoval Díaz M, de Armas Rodríguez Y, González Ochoa E, Pérez Gómez HR. Plascencia Hernández A, et al. Among authors: gonzalez ochoa e. PLoS One. 2022 Mar 10;17(3):e0264982. doi: 10.1371/journal.pone.0264982. eCollection 2022. PLoS One. 2022. PMID: 35271625 Free PMC article.
66 results